Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to ...
Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...
DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...
Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...
The following are some of the notable drug approvals that occurred in January 2025. Omvoh (mirikizumab-mrkz) Humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit ...
Ozempic (semaglutide) Glucagon-like peptide-1 receptor agonist To reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, and cardiovascular death in ...
After hours: February 14 at 7:30:13 PM EST Loading Chart for AMGN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results